 LEXINGTON, Mass.--BUSINESS WIRE--Frequency Therapeutics, Inc. Nasdaq: FREQ, a clinical-stage regenerative medicine company focused on developing therapeutics to activate a persons innate regenerative potential to restore human function, today announced that four additional sensorineural hearing loss SNHL subjects from its FX-322-111 open-label study achieved statistically significant hearing improvements when evaluated 8 to 12 months following initial dosing. Including the five initial r 